ASCO: Ramucirumab Plus Pembrolizumab Promising in NSCLC
Early research shows that overall survival is longer with ramucirumab and pembrolizumab (RP) compared with an investigator’s choice standard-of-care (SOC) in advanced non-small cell lung cancer (NSCLC).